Results 1 to 10 of about 496,062 (355)

The efficacy of premedication with 10 mg versus 20 mg of intravenous dexamethasone for prevention of paclitaxel hypersensitivity reaction in low-risk gynecologic cancer patients: a non-inferiority, randomized controlled mono-institutional trial. [PDF]

BMC Cancer
Background Dexamethasone has been used extensively to prevent hypersensitivity reactions to paclitaxel. However, the optimal dose of dexamethasone is controversial, varying between 20 mg and 10 mg.
Sa-Ngiamphorn N, Suprasert P, Charoentum C.   +2 more
europepmc   +2 more sources

Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]

New England Journal of Medicine, 2019
BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA ...
al., et, Vij, Ravi
core   +3 more sources

Impact of dexamethasone therapy on mortality in critically ill patients with non-traumatic intracerebral hemorrhage: a propensity score-matched cohort study. [PDF]

Sci Rep
Non-traumatic intracerebral hemorrhage (ICH) is the most common type of hemorrhagic stroke. The therapeutic effects of dexamethasone in ICH patients remain unclear.
Lu Y, Mao B, Tang J, Shi S, Wang M, Wan S.   +5 more
europepmc   +2 more sources

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

Cancer, 2018
The randomized phase 3 ELOQUENT‐2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab plus lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone (Ld) in relapsed/refractory multiple myeloma (RRMM), and to date, has ...
Sagar Lonial, Keith A Betts, Paul G Richardson   +2 more
exaly   +2 more sources

The Effect of the Timing of Dexamethasone Administration in Patients with COVID-19 Pneumonia [PDF]

Tuberculosis and Respiratory Diseases, 2021
Background Despite the proven benefits of dexamethasone in hospitalized coronavirus disease 2019 (COVID-19) patients, the optimum time for the administration of dexamethasone is unknown.
Hyun Woo Lee, Jimyung Park, Jung-Kyu Lee, Tae Yeon Park, Eun Young Heo   +4 more
doaj   +1 more source

Smoking in asthma is associated with elevated levels of corticosteroid resistant sputum cytokines—an exploratory study [PDF]

, 2013
<p>Background: Current cigarette smoking is associated with reduced acute responses to corticosteroids and worse clinical outcomes in stable chronic asthma. The mechanism by which current smoking promotes this altered behavior is currently unclear.
A McKay, A Sykes, B Pedersen, Carl de Wet, Charles McSharry, Christopher J. Weir, E Goleva, E Goleva, E Irusen, E Juniper, E Livingston, GJ Zijlstra, GW Chalmers, GW Chalmers, H Kerstjens, J Kam, J St-Laurent, JEM Tomlinson, M Althuis, M Broekema, M Spears, Marco Idzko, Mark Spears, MR Edwards, MR Miller, MR Stämpfli, NC Thomson, Neil C. Thomson, R Chaudhuri, R Chaudhuri, R Crapo, R Meijer, R Sher, Rekha Chaudhuri, S Holgate, SC Lazarus, SE Pedersen, SE Wenzel, WE Naugler, Z Qiu, Z Xing   +40 more
core   +12 more sources

Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone. [PDF]

PLoS ONE, 2016
Although dexamethasone is highly effective in the treatment of pediatric acute lymphoblastic leukemia (ALL), it can cause serious metabolic side effects.
Lidewij T Warris, Erica L T van den Akker, Marc B Bierings, Cor van den Bos, Christian M Zwaan, Sebastiaan D T Sassen, Wim J E Tissing, Margreet A Veening, Rob Pieters, Marry M van den Heuvel-Eibrink   +9 more
doaj   +1 more source

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

medRxiv, 2020
Background: Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death.
P. Horby, W. Lim, J. Emberson, M. Mafham, Jennifer L. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, E. Elmahi, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L. Chappell, S. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczak, J. Baillie, R. Haynes, M. Landray, -. P. C. Group   +26 more
semanticscholar   +1 more source

Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer. [PDF]

PLoS ONE, 2018
INTRODUCTION:Successful inhibition of thymidylate synthase (TS) by pemetrexed, a TS inhibitor, results in a reproducible transient burst or "flare" in thymidine salvage pathway activity at 2 hrs.
Xiao Chen, Yizeng Yang, Sharyn I Katz
doaj   +1 more source

Factors associated with the response to postnatal dexamethasone use in very low birthweight infants: a nationwide cohort study

BMJ Paediatrics Open, 2023
Background Dexamethasone is widely used as a systemic corticosteroid to treat and prevent bronchopulmonary dysplasia (BPD) in preterm infants. We evaluated the current epidemiology of dexamethasone use to prevent BPD and analyse the factors associated ...
Soon Min Lee, Min Soo Park, So Jin Yoon, In Gyu Song, Seung Hwan Baek, Jeong Eun Shin, Jungho Han, Joonsik Park, Su Min Lee, Sungbo Shim, Ho Seon Eun, Joohee Lim, Wook Chang   +12 more
doaj   +1 more source